SB 1144 is a study bill directing the Oregon Liquor and Cannabis Commission (OLCC) to examine the amount of marijuana items that a licensed marijuana retailer may sell. The measure does not itself change retail sales limits or licensing rules; instead, it requires the commission to review the issue and prepare a report, which may include recommendations for legislation.
The OLCC must submit its findings to the interim legislative committees related to business no later than September 15, 2026. The study authority is temporary and sunsets on January 2, 2027, meaning the bill is intended to gather information for possible future policy action rather than create a permanent regulatory program.
Impact
The bill would not directly amend Oregon’s cannabis statutes or alter the existing retail marijuana sales framework in ORS chapter 475C. Its immediate legal effect is to require an agency study and reporting obligation concerning retailer sales quantities, with any substantive change to marijuana sales limits deferred to future legislation if recommended. The measure affects the OLCC and, indirectly, licensed marijuana retailers by placing the issue of sales volume under formal legislative review.
Sentiment
With no committee transcript or recorded votes available, the bill appears to be a low-conflict, informational measure rather than a controversial policy change. Study bills like this are generally used to build a record for later legislation, suggesting neutral or cautious support around the need to evaluate cannabis retail limits before making changes. The absence of recorded opposition or amendments in the provided materials indicates no documented public disagreement in the available history.
Contention
The main policy question is whether Oregon should change the amount of marijuana items a retailer may sell, and if so, how such limits should be structured. Potential points of contention would likely involve cannabis retailers seeking higher sales allowances, regulators concerned about market oversight, and lawmakers weighing public health, diversion, and market management considerations. However, the provided record contains no transcript evidence of specific objections or supporters.